Table IV.
Propensity-score–matched subgroup analyses for the association of SARS-CoV-2 test positivity with asthma phenotypes among all patients who underwent SARS-CoV-2 testing and clinical outcomes or length of hospital stay with asthma phenotypes among patients with laboratory-confirmed SARS-CoV-2 infection
| Exposure | Event | Event number/total number (%) | Fully adjusted OR∗ (95% CI) |
|---|---|---|---|
| Patients who underwent SARS-CoV-2 test | |||
| None | COVID-19 | 640/29,570 (2.2) | Reference |
| Allergic asthma | 603/26,784 (2.3) | 1.06 (0.97 to 1.17) | |
| Nonallergic asthma | 80/2,786 (2.9) | 1.34 (1.07 to 1.71) | |
| Patients who tested positive for SARS-CoV-2 | |||
| None | Severe clinical outcomes of COVID-19 | 24/537 (4.5) | Reference |
| Allergic asthma | 30/493 (6.1) | 1.40 (0.83 to 2.41) | |
| Nonallergic asthma | 7/44 (15.9) | 4.09 (1.69 to 10.52) | |
| Exposure | Event | Duration (d), crude mean ± SD | Adjusted mean difference∗ (95% CI) |
|---|---|---|---|
| Patients who tested positive for SARS-CoV-2 | |||
| None | Length of stay for patients in hospital | 22.1 ± 14.1 | Reference |
| Allergic asthma | 24.1 ± 16.5 | 0.60 (−1.79 to 0.58) | |
| Nonallergic asthma | 29.3 ± 21.4 | 3.91 (0.40 to 7.42) | |
Numbers in boldface indicate significant differences (P < .05).
∗
Fully adjusted: adjustment for age, sex, region of residence, history of diabetes mellitus, cardiovascular disease, cerebrovascular disease, COPD, hypertension, chronic kidney disease, Charlson comorbidity index, use of immunosuppressants, use of systemic glucocorticoids, allergic rhinitis, and atopic dermatitis.